Raven and have agreed to invest $3.8 million to close the merger.
-- VaxGen has indeed repurchased, at a discount, a portion ($1.5 million)
of its convertible debt; the only portion for which we have received a
formal repurchase offer to date.
-- No member of the proposed senior management team of the combined
company is being, or ever has been, sued by a current or former
-- No formal offers have been received to date for two of VaxGen's assets,
the manufacturing facility and the anthrax vaccine program, despite
extensive efforts of management and professional advisors to market
these assets, nor has VaxGen received any unsolicited, alternative
offer to this merger.
The dissenting stockholders offer no tangible alternatives to the merger and indeed do not appear to agree amongst themselves as to the right course to pursue. In the event that our stockholders do not approve the merger with Raven, liquidation is perhaps the most likely alternative. However, VaxGen believes this option to be far inferior to the proposed merger in that the proceeds would be limited, with no possibility of any future upside from continuing operations, and would only be distributed to stockholders following an extensive, time consuming and expensive process.
The combined company will be both technically and financially well
positioned within one of the most dynamic sectors in drug development. We
are encouraged that several new biotech investors and analysts also see the
value in the merged company we are proposing. For example, in her Morning
Meeting Comments issued March 18th, Sharon R. Seiler, Ph.D., Senior
Biotechnology Analyst of Punk, Z
|SOURCE VaxGen Inc.|
Copyright©2008 PR Newswire.
All rights reserved